Q1 EPS Estimates for TLSI Decreased by Northland Securities

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Equities researchers at Northland Securities decreased their Q1 2026 EPS estimates for TriSalus Life Sciences in a research report issued to clients and investors on Monday, March 23rd. Northland Securities analyst C. Byrnes now anticipates that the company will post earnings per share of ($0.16) for the quarter, down from their prior estimate of ($0.12). The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Northland Securities also issued estimates for TriSalus Life Sciences’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.45) EPS and FY2027 earnings at ($0.25) EPS.

Several other equities research analysts have also issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Canaccord Genuity Group decreased their target price on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Finally, Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, TriSalus Life Sciences has an average rating of “Hold” and a consensus price target of $7.00.

TriSalus Life Sciences Price Performance

TLSI opened at $3.92 on Wednesday. The firm has a market capitalization of $240.34 million, a P/E ratio of -2.14 and a beta of 0.42. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $7.95. The company has a fifty day moving average price of $4.75 and a 200-day moving average price of $5.26.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $13.21 million for the quarter, compared to the consensus estimate of $13.20 million.

Insider Activity

In other news, CEO Mary T. Szela sold 15,944 shares of TriSalus Life Sciences stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.85, for a total transaction of $61,384.40. Following the completion of the sale, the chief executive officer directly owned 752,987 shares of the company’s stock, valued at approximately $2,898,999.95. The trade was a 2.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 30,150 shares of company stock worth $119,849. Insiders own 27.50% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC bought a new stake in TriSalus Life Sciences during the second quarter worth about $10,900,000. AWM Investment Company Inc. bought a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at about $6,812,000. Vanguard Group Inc. raised its holdings in shares of TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after buying an additional 345,186 shares in the last quarter. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after buying an additional 265,618 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after buying an additional 235,627 shares during the last quarter. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.